ENDOCYTE INC Contracts & Agreements

85 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Form of Amendment to Change in Control and Severance Agreement
Change of Control Agreements
ENDOCYTE INC
2018
Agreement and Plan of Merger, dated as of October 17, 2018, by and among Novartis AG, Edinburgh Merger Corporation and Endocyte, Inc
Merger Agreements
ENDOCYTE INC
2018
Underwriting Agreement, dated as of September 11, 2018, by and among the Company and Jefferies LLC, Wells Fargo Securities, LLC, and RBC Capital Markets, LLC, as representatives...
Underwriting Agreements
ENDOCYTE INC
2018
Fifth Amendment to Office Lease dated May 29, 2018 between Endocyte, Inc. and Tempus One College Park LLC as successor in interest to Zeller Management Corporation
Lease Agreements
ENDOCYTE INC
2018
Second Amendment of Lease dated June 14, 2018 between Endocyte, Inc. and Purdue Research Foundation
Lease Agreements
ENDOCYTE INC
2018
Form of 2010 Equity Incentive Plan Time-Based Restricted Stock Unit Award Agreement (Employees) (for use after July 18, 2018)
Bonus & Incentive Agreements
ENDOCYTE INC
IN
2018
Form of 2010 Equity Incentive Plan Stock Option Award Agreement (Employees) (for use after July 18, 2018)
Bonus & Incentive Agreements
ENDOCYTE INC
IN
2018
Form of 2010 Equity Incentive Plan Time-Based Restricted Stock Unit Award Agreement (Directors Initial Grants) (for use after July 18, 2018)
Bonus & Incentive Agreements
ENDOCYTE INC
IN
2018
Form of 2010 Equity Incentive Plan Stock Option Award Agreement (Directors Initial Grants) (for use after July 18, 2018)
Bonus & Incentive Agreements
ENDOCYTE INC
2018
Form of 2010 Equity Incentive Plan Time-Based Restricted Stock Unit Award Agreement (Directors Annual Grants) (for use after July 18, 2018)
Bonus & Incentive Agreements
ENDOCYTE INC
IN
2018
Form of 2010 Equity Incentive Plan Stock Option Award Agreement (Directors Annual Grants) (for use after July 18, 2018)
Bonus & Incentive Agreements
ENDOCYTE INC
IN
2018
Global Supply Agreement, dated as of July 5, 2018, between Endocyte, Inc. and ITG Isotope Technologies Garching GmbH
Supply Agreements
ENDOCYTE INC
IN
2018
Fourth Amendment to Office Lease dated January 26, 2018 between Endocyte, Inc. and Tempus One College Park LLC as successor in interest to Zeller Management Corporation
Lease Agreements
ENDOCYTE INC
2018
Underwriting Agreement, dated as of February 28, 2018, by and among the Company and Jefferies LLC, Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc., as...
Underwriting Agreements
ENDOCYTE INC
NY
2018
Amendment #20 to the Amended and Restated Exclusive License Agreement dated October 21, 1998 between Endocyte, Inc. and Purdue Research Foundation, as amended
License Agreements
ENDOCYTE INC
2018
Amendment #3 to the Exclusive License Agreement effective March 1, 2010 between Endocyte, Inc. and Purdue Research Foundation, as amended
License Agreements
ENDOCYTE INC
2018
Amendments #9 and #10 to the Master License Agreement effective July 1, 2013 between Endocyte, Inc. and Purdue Research Foundation, as amended
License Agreements
ENDOCYTE INC
2018
First Amendment of lease dated November 10, 2017 between Endocyte, Inc. and Purdue Research Foundation
Lease Agreements
ENDOCYTE INC
2018
chedule of Terms for Change in Control and Severance Agreements with Executive Officers
Change of Control Agreements
ENDOCYTE INC
2018
Form of Warrant to Purchase Shares of Common Stock, dated as of September 29, 2017
Warrant Agreements
ENDOCYTE INC
DE
2017
Registration Rights Agreement, dated as of September 29, 2017, between Endocyte, Inc. and ABX advanced biochemical compounds Biomedizinische Forschungsreagenzien GmbH
Registration Rights Agreements
ENDOCYTE INC
DE
2017
AMENDMENT #14 TO LICENSE AGREEMENT ID LA0003Endocyte Between Purdue Research Foundation and Endocyte Corporation
License Agreements
ENDOCYTE INC
2017
Second Amendment to the Amended and Restated License Agreement made effective on March 1, 2010 between the Purdue Research Foundation and Endocyte, Inc. (“Agreement”)
License Agreements
ENDOCYTE INC
2017
AMENDMENT #1 TO LICENSE AGREEMENT ID 2014-0052 Between Purdue Research Foundation and Endocyte, Inc.
License Agreements
ENDOCYTE INC
2017
PURDUE TECHNOLOGY CENTER 3000 Kent Avenue West Lafayette, Indiana 47906 EXTENSION OF LEASE
Lease Agreements
ENDOCYTE INC
2017
SEPARATION AGREEMENT AND RELEASE OF CLAIMS
Separation Agreements
ENDOCYTE INC
2017
ENDOCYTE, INC. SCHEDULE OF TERMS FOR CHANGE IN CONTROL AND SEVERANCE AGREEMENTS WITH EXECUTIVE OFFICERS March 2017
Change of Control Agreements
ENDOCYTE INC
2017
SEPARATION AGREEMENT AND RELEASEOF CLAIMS
Separation Agreements
ENDOCYTE INC
2016
WARRANT TO PURCHASE SHARES OF COMMONSTOCK
Warrant Agreements
ENDOCYTE INC
IN
2016
PURDUE TECHNOLOGY CENTER 3000KENT AVENUE WESTLAFAYETTE, INDIANA 47906 LEASE AGREEMENT
Lease Agreements
ENDOCYTE INC
2016
ENDOCYTE, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT
Change of Control Agreements
ENDOCYTE INC
2015
MASTER LICENSE AGREEMENT Between PURDUE RESEARCH FOUNDATION and ENDOCYTE, INC. TABLE OF CONTENTS
License Agreements
ENDOCYTE INC
IN
2015
SEPARATION AGREEMENT AND RELEASEOF CLAIMS
Separation Agreements
ENDOCYTE INC
IN
2014
FOURTH AMENDMENT OF LEASE AGREEMENT
Lease Agreements
ENDOCYTE INC
2014
LICENSE AGREEMENT BETWEEN ENDOCYTE, INC AND PURDUE RESEARCH FOUNDATION OCTOBER 21, 1998
License Agreements
ENDOCYTE INC
2014
EXCLUSIVE LICENSE AGREEMENT
License Agreements
ENDOCYTE INC
2014
THIRD AMENDMENT OF LEASE AGREEMENT
Lease Agreements
ENDOCYTE INC
2014
4,500,000 Shares ENDOCYTE, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreements
ENDOCYTE INC
NY
2014
PURDUE TECHNOLOGY CENTER 3000kent avenue westlafayette, indiana 47906 EXTENSION OF LEASE
Lease Agreements
ENDOCYTE INC
2014
ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN TIME-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT
Bonus & Incentive Agreements
ENDOCYTE INC
IN
2014
Endocyte,Inc. $60,000,000 COMMON STOCK SALES AGREEMENT
Stock Agreements
ENDOCYTE INC
2013
SECOND AMENDMENT OF LEASE AGREEMENT
Lease Agreements
ENDOCYTE INC
2013
WARRANT TO PURCHASE SHARES OF COMMON STOCK OF ENDOCYTE, INC.
Warrant Agreements
ENDOCYTE INC
IN
2013
FIRST AMENDMENT OF LEASE AGREEMENT
Lease Agreements
ENDOCYTE INC
2013
THIRDAMENDMENT TO OFFICE LEASE
Lease Agreements
ENDOCYTE INC
2013
PURDUE TECHNOLOGY CENTER 3000kent avenue westlafayette, indiana 47906 LEASE AGREEMENT
Lease Agreements
ENDOCYTE INC
2013
COLLABORATION, EXCLUSIVE LICENSE, AND COMPANION DIAGNOSTIC AGREEMENT by and between Merck Sharp & Dohme Research GmbHand ENDOCYTE, INC.
Collaboration Agreements
ENDOCYTE INC
NY
2012
Lease Agreement
Lease Agreements
ENDOCYTE INC
IN
2012
PURDUE TECHNOLOGY CENTER 3000 KENT AVENUE WEST LAFAYETTE, IN 47906 EXTENSION OF LEASE
Lease Agreements
ENDOCYTE INC
2012
THIRD LOAN MODIFICATION AGREEMENT
Loan Agreements
ENDOCYTE INC
MD
2011
[ ] Shares Endocyte, Inc. Common Stock ($0.001 Par Value) UNDERWRITING AGREEMENT
Underwriting Agreements
ENDOCYTE INC
2011
SECOND LOAN MODIFICATION AGREEMENT
Loan Agreements
ENDOCYTE INC
MD
2011
ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (2011 RSU PROGRAM)
Bonus & Incentive Agreements
ENDOCYTE INC
IN
2011
Current assets
ENDOCYTE INC
2011
Current assets
ENDOCYTE INC
2011
Obtain marketing approval of our phase 3-ready SMDC, EC145, for use in women with platinum-resistant ovarian cancer. We plan to initiate a randomized, controlled, double-blinded...
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
MD
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
NY
2010